Clicky

ELEDON PHARMACEUT.DL-001(2TK)

Description: Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for kidney transplantation, xenotransplantation, and liver transplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.


Keywords: Biotechnology Antibody Transplantation Amyotrophic Lateral Sclerosis Organ Transplantation Clusters Of Differentiation Kidney Transplantation Cd40 Seth Lederman

Home Page: eledon.com

19900 MacArthur Boulevard
Irvine, CA 92612
United States
Phone: (949) 238-8090


Officers

Name Title
Dr. David-Alexandre C. Gros M.D., Ph.D. CEO & Non Independent Director
Dr. Steven N. Perrin Ph.D. President, Chief Scientific Officer & Non Independent Director
Mr. Paul Sean Little Chief Financial Officer
Mr. John Herberger Vice President of Technical Operations
Mr. Bryan E. Smith J.D. General Counsel, Corporate Secretary & Chief Compliance Officer
Dr. David Hovland Ph.D. Chief Regulatory Officer
Dr. Eliezer Katz F.A.C.S., FACS, M.D. Chief Medical Officer

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 5.3135
Trailing PE: 5.8551
Price-to-Book MRQ: 3.3589
Price-to-Sales TTM: 0
IPO Date:
Fiscal Year End: December
Full Time Employees: 20
Back to stocks